Eliberarea treptată a anticorpilor și substanțelor antimicrobiene (lizozimul, ovomucina și ovotransferina) fac din Dentoimmune pulbere un mijloc terapeutic eficient în sterilizarea canalelor radiculare, putând fi folosit în combinație cu diferite paste de canal (cu hidrixid de calciu, silicat de calciu, cu antibiotice). Poate fi folosit și în scopul prevenirii complicațiilor postoperatorii în cazul intervențiilor chirurgicale (implantologie, parodontologie, extracții dentare, augmentări osoase, rezecții apicale, odontectomii, alveolite, etc.), aplicându-se direct în site-ul chirurgical, putând fi asociat și cu alte substanțe terapeutice (antibiotice, material de augmentare de orice tip, PRP, A-PRF, I-PRF, L-PRF, PRGF, etc.).

  • Prospect


Blood antibodies production in birds and the extraction of egg yolk specific antibodies has become an attractive subject for specialists, as evidenced by the increase in research volume and literature on IgY. The results of in vitro and in vivo studies on immunoglobulins (Y) extracted from egg yolk (Gallus domesticus) have become a great hope in preventing and fighting a large number of human diseases. Interest in immunoglobulins prepared on the hen is currently high due to the increasing incidence of antibiotic-resistant bacteria. IgY gains much attention from specialists due to structural differences from mammalian IgG and reactivity in the human body. The special features of this product create a hope for medicine, IgY being used in many areas of activity. Within the research program, studies are carried out on the procedures for obtaining IgY under laboratory and production conditions. At the same time, experiments were carried out on the purification of IgY and the specificity of these immunoglobulins was studied against the antigens that were used to immunize the hens. Biological products containing specific IgY are monovalent or polyvalent.  Y immunoglobulins were obtained from the isolated bacteria samples collected from patients who presented themselves in our dental clinic with many of these bacteria proving antibiotic resistant.  Laboratory tests have been performed on IgY-specific efficacy against antibiotic-resistant bacteria isolated from patients. The results of the experiments conducted so far show that specific IgY inhibit in vitro the multiplication of antibiotic-resistant bacteria. Depending on the intensity of the specific inhibited bacterial multiplication, as well as on the inhibition time in vitro, therapeutic behavior can be established. Under these conditions, single-dose treatment at 24 hours or fractionalized doses at different time intervals may occur. Recent in vitro information on IMUNOINSTANT products against isolated bacteria from patients allows for more effective treatment programs for humans, IgY inhibiting specific large amounts of pathogenic germs, whose action is thus neutralized. For this purpose, treatment should be permanently controlled by laboratory means, and the program should be monitored appropriately. Preventive treatment with IgY will be determined based on isolated bacteria and incidence. Depending on their number, a polyvalent IgY comprising immunoglobulins specific for each bacterial species will be prepared.